Home Corrigendum to: Formulation of a 3-months Stability Oral Viscous Budesonide Gel and Development of an Indicating Stability HPLC Method
Article Publicly Available

Corrigendum to: Formulation of a 3-months Stability Oral Viscous Budesonide Gel and Development of an Indicating Stability HPLC Method

This erratum corrects the original online version which can be found here: https://doi.org/10.1515/pthp-2018-0005
  • Mathilde Bonnet EMAIL logo , Marine Dermu , Clara Roessle , Marc Bellaiche , Tarik Abarou , Véronique Vasseur , Samira Benakouche and Thomas Storme
Published/Copyright: April 11, 2019
Become an author with De Gruyter Brill

Corrigendum to: Mathilde Bonnet, Marine Dermu, Clara Roessle, Marc Bellaiche, Tarik Abarou, Véronique Vasseur, Samira Benakouche and Thomas Storme. Formulation of a 3-months Stability Oral Viscous Budesonide Gel and Development of an Indicating Stability HPLC Method. Pharmaceutical Technology in Hospital Pharmacy. Volume 3, Issue 2, pages 91–99. (DOI https://doi.org/10.1515/pthp-2018-0005)

In Table 1, on page 94, the formulation was based on the original formula published by Eyal Zur, compounding pharmacist and consultant from Israel, in the International Journal of Pharmaceutical Coupounding in 2012. [1]

[1] Zur, E. 2012. Eosinophilic esophagitis: treatment with oral viscous budesonide. Int. J. Pharm. Compd. 16: 288–293.

Received: 2019-02-14
Revised: 2019-03-21
Accepted: 2019-03-21
Published Online: 2019-04-11
Published in Print: 2019-05-02

© 2019 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 8.10.2025 from https://www.degruyterbrill.com/document/doi/10.1515/pthp-2018-9005/html?licenseType=free
Scroll to top button